We discovered some positive trends after analyzing the financial performance of the 16 largest, pure biopharmaceutical companies over the past 7 years.
From 2013 on, our findings show:
-
The negative impact from sales lost to patent expiration peaked in 2012 and will lessen.
-
The ratio of revenue from the pipeline and current portfolio compared to sales lost from patent expiry will improve.
-
Select companies are showing notably improved performance.
-
Investors are looking beyond the patent crisis and valuing companies that have clearly articulated a path to sustainable growth and are making substantial strategic and operational changes to achieve their growth objectives.
To see a snapshot of our key findings and learn the moves top industry players made to return to profitable growth, please scroll down.
